Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha

Acta Oncologica

Volumn 41, Issue 1, 2002, Pages 50-55

  Merup, Mats ^a   Åberg, Wiveca ^a   Löfvenberg, Eva ^a   Svensson, Else ^a   Engman, Katarina ^a   Paul, Christer ^a   Gardulf, Ann ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; HEALTH HAZARDS; MUSCLE;

SIDE EFFECTS;

PATIENT TREATMENT;

ALPHA INTERFERON;

ADULT; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; LIFE EXPECTANCY; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SYMPTOMATOLOGY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DEPRESSION; FEMALE; HEALTH STATUS; HUMANS; INTERFERON-ALPHA; MALE; MEDICAL RECORDS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYCYTHEMIA VERA; QUALITY OF LIFE; QUESTIONNAIRES; SELF ASSESSMENT (PSYCHOLOGY); SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL; SWEDEN; THROMBOCYTHEMIA, HEMORRHAGIC; TIME FACTORS;

EID: 0036215494     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602317314064     Document Type: Article

References (21)

1. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
2. Polycythemia rubra vera
3. Essential thrombocythemias, clinical evolutionary and biological data
4. Acute transformation in nonleukemic chronic lyeloproliferative disorders; actuarial probability and main characteristics in a series of 218 patients
5. Leukomogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis
6. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea; high proportion of cases with 17p deletion
7. Treatment of essential thrombocythemia with anagrelide
8. Alpha-interferon in polycythemia vera and essential thrombocythemia
9. Recombinant interferon a-2b in the treatment of polycythenmia vera
10. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia
11. Primary thrombocythemia and pregnancy; treatment and outcome in fifteen cases
12. The alpha interferons: Clinical overview
13. Interferon-beta treatment for patients with multiple sclerosis: The patients' perceptions of the side effects
14. The Swedish Health-Related Quality of Life Survery (SWED-QUAL)
15. Fatigue in patients with cancer receiving interferon alpha
16. Randomized trials with quality of life endpoints: Are doctor ratings of patients' physical symptoms interchangeable with patients' self-ratings?
17. Are healthcare providers adequate raters of patients' quality of life - Perhaps more than we think
18. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review
19. Evaluating the quality of life of cancer patients: Assessment by patients, significant others, physicians and nurses
20. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients